[1]王镜媛,寿松涛.血必净联合胸腺肽α1治疗重症肺炎合并脓毒症的效果[J].医学信息,2020,33(16):169-171.[doi:10.3969/j.issn.1006-1959.2020.16.056]
　WANG Jing-yuan,SHOU Song-tao.The Effect of Xuebijing Combined with Thymosin α1 in the Treatment of Severe Pneumonia Complicated with Sepsis[J].Medical Information,2020,33(16):169-171.[doi:10.3969/j.issn.1006-1959.2020.16.056]
点击复制

血必净联合胸腺肽α1治疗重症肺炎合并脓毒症的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年16期
页码:
169-171
栏目:
中医中药
出版日期:
2020-08-15

文章信息/Info

Title:
The Effect of Xuebijing Combined with Thymosin α1 in the Treatment of Severe Pneumonia Complicated with Sepsis
文章编号:
1006-1959（2020）16-0169-03
作者:
王镜媛; 寿松涛
（天津医科大学总医院急诊医学科，天津 300052）
Author(s):
WANG Jing-yuan; SHOU Song-tao
(Department of Emergency Medicine,General Hospital of Tianjin Medical University,Tianjin 300052,China)
关键词:
血必净; 胸腺肽α1; 肺炎合并脓毒症
Keywords:
Xuebijing; Thymosin α1; Pneumonia with sepsis
分类号:
R969
DOI:
10.3969/j.issn.1006-1959.2020.16.056
文献标志码:
A
摘要:
目的 观察血必净联合胸腺肽α1用于重症肺炎合并脓毒症的治疗效果。方法 选取2018年2月~2019年8月在我院治疗的47例重症肺炎合并脓毒症患者为研究对象，采用随机数字表法分为对照组（n=24）和观察组（n=23）。对照组采用血必净治疗，观察组在对照组基础上联合胸腺肽α1治疗，比较两组临床治疗总有效率、细菌清除率、治疗前后呼吸、心率、炎症指标[白细胞计数（WBC）、血清白细胞介素-6（IL-6）、血清肿瘤坏死因子α（TNF-α）、血清前降钙素（PCT）、C反应蛋白（CRP）]、血气指标[二氧化碳分压（PaCO2）、动脉血氧分压（PaO2）]及不良反应发生情况。结果 观察组治疗总有效率为91.30%，高于对照组的79.16%，差异有统计学意义（P＜0.05）；观察组细菌清除率为82.61%，高于对照组的70.83%，差异有统计学意义（P＜0.05）；治疗后两组WBC、IL-6、TNF-α、PCT、CRP均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；治疗后两组后PaCO2水平低于治疗前，PaO2水平高于治疗前，且观察组PaCO2水平低于对照组，PaO2水平高于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为13.04%，与对照组的12.50%比较，差异无统计学意义（P＞0.05）。结论 重症肺炎合并脓毒症采用血必净联合胸腺肽α1治疗有效率和细菌清除率高，炎症减轻，血气改善，且临床不良反应少，应用安全可靠。
Abstract:
Objective To observe the therapeutic effect of Xuebijing combined with thymosin α1 for severe pneumonia combined with sepsis.Methods 47 patients with severe pneumonia combined with sepsis who were treated in our hospital from February 2018 to August 2019 were selected as the research objects. They were divided into the control group (n=24) and the observation group (n=23) by random number table method.The control group was treated with Xuebijing, and the observation group was treated with thymosin α1 on the basis of the control group. The total effective rate of clinical treatment, bacterial clearance, respiration, heart rate, and inflammation indicators [white blood cell count (WBC), serum white blood cell Interleukin-6 (IL-6), serum tumor necrosis factor alpha (TNF-α), serum procalcitonin (PCT), C-reactive protein (CRP)], blood gas indicators [partial pressure of carbon dioxide (PaCO2), arterial blood Partial pressure of oxygen (PaO2)] and the occurrence of adverse reactions.Results The total effective rate of treatment in the observation group was 91.30%, which was higher than 79.16% in the control group,the difference was statistically significant (P＜0.05); the bacterial clearance rate in the observation group was 82.61%, which was higher than 70.83% in the control group,the difference was statistically significant(P＜0.05); WBC, IL-6, TNF-α, PCT and CRP in the two groups after treatment were lower than those before treatment, and the observation group was lower than the control group, the difference was statistically significant (P＜0.05); The PaCO2 level after the latter two groups was lower than before treatment, the PaO2 level was higher than before treatment, and the PaCO2 level of the observation group was lower than that of the control group, and the PaO2 level was higher than that of the control group, the difference was statistically significant (P＜0.05); adverse reactions in the observation group the incidence rate was 13.04%, compared with 12.50% in the control group, the difference was not statistically significant (P＞0.05).Conclusion Xuebijing combined with thymosin α1 for severe pneumonia combined with sepsis has a high effective rate and high bacterial clearance rate, reduced inflammation, improved blood gas, and few clinical adverse reactions. The application is safe and reliable.

参考文献/References:

[1]冯娜娜,朱晓丹,李静,等.重症肺炎和脓毒血症抗凝治疗的时机和策略[J].中华结核和呼吸杂志,2015,38(3):211-214.[2]喻文,罗红敏.血必净可通过抑制蛋白酶激活受体１信号途径减轻热损伤诱导的内皮屏障破坏[J].中华危重病急救医学,2015(8):648-649.[3]方勤,蒋刚健,陈鑫.血必净注射液对急性脓毒症患者Th1/2、内毒素及免疫因子影响研究[J].中国生化药物杂志,2015(5):130-133.[4]戴丽星,何静.乌司他丁联合胸腺肽α１对脓毒症患者免疫调理的临床疗效分析[Ｊ].临床急诊杂志,2014,15(7):420－422.[5]朱志德,熊峰,刘文德.胸腺肽治疗脓毒症研究分析[J].黑龙江医药,2016,29(4):681-683.

相似文献/References:

[1]赵建美,邵 岩.血必净治疗社区获得性肺炎的研究进展[J].医学信息,2018,31(02):20.[doi:10.3969/j.issn.1006-1959.2018.02.009]
　ZHAO Jian-mei,SHAO Yan.Research Progress of Xuebijing in Treating Community Acquired Pneumonia[J].Medical Information,2018,31(16):20.[doi:10.3969/j.issn.1006-1959.2018.02.009]
[2]张恺悦,陈幼琼.乌司他丁联合血必净对烧伤后脓毒症患者凝血功能及全身炎性反应的影响研究[J].医学信息,2019,32(04):138.[doi:10.3969/j.issn.1006-1959.2019.04.044]
　ZHANG Kai-yue,CHEN You-qiong.Effect of Ulinastatin Combined with Xuebijing on Coagulation Function and Systemic Inflammatory Response in Patients with Sepsis after Burn[J].Medical Information,2019,32(16):138.[doi:10.3969/j.issn.1006-1959.2019.04.044]
[3]邓 伟.血必净注射液预防STEMI患者直接介入治疗后冠脉无复流的效果[J].医学信息,2020,33(17):163.[doi:10.3969/j.issn.1006-1959.2020.17.049]
　DENG Wei.Effect of Xuebijing Injection in Preventing Coronary Artery No-reflow After Direct Interventional Therapy in STEMI Patients[J].Medical Information,2020,33(16):163.[doi:10.3969/j.issn.1006-1959.2020.17.049]
[4]王 凯,田国栋.连续血液净化联合血必净对ARDS患者氧化应激、APACHEⅡ评分的影响[J].医学信息,2021,34(22):130.[doi:10.3969/j.issn.1006-1959.2021.22.040]
　WANG Kai,TIAN Guo-dong.Effect of Continuous Blood Purification Combined with Xuebijing on Oxidative Stress and APACHEⅡ Score in ARDS Patients[J].Medical Information,2021,34(16):130.[doi:10.3969/j.issn.1006-1959.2021.22.040]
[5]张文旭,徐 绸.血必净联合连续肾脏替代治疗对感染性休克患者的疗效及对血液循环状态的影响[J].医学信息,2022,35(04):153.[doi:10.3969/j.issn.1006-1959.2022.04.040]
　ZHANG Wen-xu,XU Chou.Effect of Xuebijing Combined with Continuous Renal Replacement Therapy on Patientswith Septic Shock and its Effect on Blood Circulation[J].Medical Information,2022,35(16):153.[doi:10.3969/j.issn.1006-1959.2022.04.040]
[6]谭秋清.胸腺肽α1在肺结核合并2型糖尿病中的应用效果及对患者免疫应答水平的影响[J].医学信息,2022,35(07):124.[doi:10.3969/j.issn.1006-1959.2022.07.031]
　TAN Qiu-qing.Application Effect of Thymosin α1 in Pulmonary Tuberculosis Complicated with Type 2 Diabetes Mellitus and its Effect on Immune Response Level[J].Medical Information,2022,35(16):124.[doi:10.3969/j.issn.1006-1959.2022.07.031]
[7]张 姝.血必净联合激素在脓毒血症急诊处理中的疗效研究[J].医学信息,2022,35(19):89.[doi:10.3969/j.issn.1006-1959.2022.19.024]
　ZHANG Shu.Study on Curative Effect of Xuebijing Combined with Hormone in Emergency Treatment of Sepsis[J].Medical Information,2022,35(16):89.[doi:10.3969/j.issn.1006-1959.2022.19.024]

更新日期/Last Update: 1900-01-01